LT3297654T - Hipoglikemijos, atsiradusios po bariatrinės chirurgijos, gydymas eksendinu(9-39) - Google Patents

Hipoglikemijos, atsiradusios po bariatrinės chirurgijos, gydymas eksendinu(9-39)

Info

Publication number
LT3297654T
LT3297654T LTEPPCT/US2016/033837T LT16033837T LT3297654T LT 3297654 T LT3297654 T LT 3297654T LT 16033837 T LT16033837 T LT 16033837T LT 3297654 T LT3297654 T LT 3297654T
Authority
LT
Lithuania
Prior art keywords
exendin
post
treatment
bariatric hypoglycemia
bariatric
Prior art date
Application number
LTEPPCT/US2016/033837T
Other languages
English (en)
Inventor
Tracey L. MCLAUGHLIN
Colleen M. CRAIG
Original Assignee
The Board Of Trustees Of The Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Board Of Trustees Of The Leland Stanford Junior University filed Critical The Board Of Trustees Of The Leland Stanford Junior University
Publication of LT3297654T publication Critical patent/LT3297654T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
LTEPPCT/US2016/033837T 2015-05-22 2016-05-23 Hipoglikemijos, atsiradusios po bariatrinės chirurgijos, gydymas eksendinu(9-39) LT3297654T (lt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562165743P 2015-05-22 2015-05-22
US201562254175P 2015-11-11 2015-11-11
US201662329850P 2016-04-29 2016-04-29
PCT/US2016/033837 WO2016191395A1 (en) 2015-05-22 2016-05-23 Treatment of post-bariatric hypoglycemia with exendin(9-39)

Publications (1)

Publication Number Publication Date
LT3297654T true LT3297654T (lt) 2021-10-25

Family

ID=57393681

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEPPCT/US2016/033836T LT3297653T (lt) 2015-05-22 2016-05-23 Postbariatrinės hipoglikemijos gydymas glp-1 antagonistais
LTEPPCT/US2016/033837T LT3297654T (lt) 2015-05-22 2016-05-23 Hipoglikemijos, atsiradusios po bariatrinės chirurgijos, gydymas eksendinu(9-39)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2016/033836T LT3297653T (lt) 2015-05-22 2016-05-23 Postbariatrinės hipoglikemijos gydymas glp-1 antagonistais

Country Status (17)

Country Link
US (8) US10660937B2 (lt)
EP (4) EP3936143A1 (lt)
AU (4) AU2016267057B2 (lt)
BR (2) BR112017025000A2 (lt)
CA (2) CA3024358A1 (lt)
CL (2) CL2017002913A1 (lt)
CY (2) CY1124616T1 (lt)
DK (2) DK3297653T3 (lt)
ES (2) ES2887723T3 (lt)
HR (2) HRP20211768T1 (lt)
HU (2) HUE057301T2 (lt)
LT (2) LT3297653T (lt)
PL (2) PL3297653T3 (lt)
PT (2) PT3297653T (lt)
RS (2) RS62627B1 (lt)
SI (2) SI3297654T1 (lt)
WO (2) WO2016191394A1 (lt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008085982A2 (en) 2007-01-08 2008-07-17 The Trustees Of The University Of Pennsylvania Methods and compositions for treating hypoglycemic disorders
ES2887723T3 (es) 2015-05-22 2021-12-27 Univ Leland Stanford Junior Tratamiento de hipoglucemia posbariátrica con exendina(9-39)
WO2017152014A1 (en) 2016-03-04 2017-09-08 Eiger Biopharmaceuticals, Inc. Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
CN110267648A (zh) 2016-11-21 2019-09-20 艾格尔峰生物制药有限公司 毒蜥外泌肽(9-39)的缓冲制剂
KR20200134213A (ko) * 2018-01-23 2020-12-01 엑스에리스 파머수티클스, 인크. 소 용량의 안정한 글루카곤을 사용한 베리아트릭 후 저혈당증의 치료
GB201816639D0 (en) * 2018-10-12 2018-11-28 Heptares Therapeutics Ltd GLP-1 Receptor Antagonist
BR112021006968A2 (pt) * 2018-10-15 2021-07-27 Eiger Biopharmaceuticals, Inc avexitide para o tratamento da hipoglicemia hiperinsulinêmica
EP3908274A1 (en) * 2019-01-11 2021-11-17 Universitätsspital Basel Sglt-2 inhibitors or il-1r antagonists for reduction of hypoglycaemia after bariatric surgery
WO2024042518A1 (en) * 2022-08-21 2024-02-29 M. Arkin (1999) Ltd Glp-1 receptor antagonist and methods of use thereof

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993025579A1 (en) 1992-06-15 1993-12-23 Pfizer Inc. Glucagon-like peptide and insulinotropin derivatives
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US20040092443A1 (en) 1996-08-06 2004-05-13 Yeda Research And Development Co., Ltd Long-acting exendins and exendin agonists
PT966297E (pt) 1996-08-08 2009-03-18 Amylin Pharmaceuticals Inc Regulação da motilidade gastrintestinal
US6956026B2 (en) 1997-01-07 2005-10-18 Amylin Pharmaceuticals, Inc. Use of exendins for the reduction of food intake
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
DE69900026T2 (de) 1998-01-30 2001-05-10 Novo Nordisk As Eine injektionsspritze
PT1137413E (pt) 1998-12-10 2005-05-31 Agouron Pharma Antagonistas nao-peptidicos do receptor de glp-1 e metodos de utilizacao
NZ512657A (en) 1999-01-14 2004-01-30 Amylin Pharmaceuticals Inc Glucagon suppression
DE60021166T3 (de) 1999-01-14 2019-08-22 Amylin Pharmaceuticals, Llc Neue exendin agonist formulierungen und deren verabreichung
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US6903074B1 (en) 1999-06-04 2005-06-07 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Neuromedin b and somatostatin receptor agonists
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US6479065B2 (en) 2000-08-10 2002-11-12 Alkermes Controlled Therapeutics, Inc. Process for the preparation of polymer-based sustained release compositions
US6824822B2 (en) 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
SE0004462D0 (sv) 2000-12-04 2000-12-04 Pharmacia Ab Novel method and use
WO2002066062A2 (en) 2001-02-01 2002-08-29 Drucker Daniel J Enhancement of glp-2 activity
AU2002257132A1 (en) 2001-04-06 2002-10-21 The Trustees Of The University Of Pennsylvania Erbb interface peptidomimetics and methods of use thereof
US7238663B2 (en) 2001-08-28 2007-07-03 Eli Lilly And Company Pre-mixes of GLP-1 and basal insulin
US7378385B2 (en) 2002-08-08 2008-05-27 University Of Cincinnati Role for GLP-1 to mediate responses to disparate stressors
ES2660320T3 (es) 2003-11-20 2018-03-21 Novo Nordisk A/S Formulaciones peptídicas que contienen propilenglicol que son óptimas para la producción y para el uso en dispositivos de inyección
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
ES2536235T3 (es) 2004-04-15 2015-05-21 Alkermes Pharma Ireland Limited Dispositivo polimérico de liberación prolongada
US7456254B2 (en) 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
DE102004043153B4 (de) 2004-09-03 2013-11-21 Philipps-Universität Marburg Erfindung betreffend GLP-1 und Exendin
EP1888031B1 (en) 2005-06-06 2013-01-23 Camurus Ab Glp-1 analogue formulations
RU2421237C2 (ru) 2005-08-19 2011-06-20 Амилин Фармасьютикалз, Инк. Способы лечения диабета и снижения массы тела
EP2035450A2 (en) 2006-05-26 2009-03-18 Amylin Pharmaceuticals, Inc. Composition and methods for treatment of congestive heart failure
WO2008085982A2 (en) 2007-01-08 2008-07-17 The Trustees Of The University Of Pennsylvania Methods and compositions for treating hypoglycemic disorders
DE102007016811A1 (de) 2007-04-05 2008-10-09 Tecpharma Licensing Ag Vorrichtung zur Verabreichung eines fluiden Wirkstoffes aus einer Mehrkammerampulle
ATE516834T1 (de) 2007-04-05 2011-08-15 Tecpharma Licensing Ag Verabreichungsvorrichtung mit funktionalem antriebsglied
WO2008133908A2 (en) 2007-04-23 2008-11-06 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
US20110046053A1 (en) 2008-05-05 2011-02-24 Oramed Ltd. Methods and compositions for oral administration of exenatide
WO2009143285A2 (en) 2008-05-21 2009-11-26 Amylin Pharmaceuticals, Inc. Exendins to lower cholestrol and triglycerides
US8071537B2 (en) 2008-06-25 2011-12-06 Endo Pharmaceuticals Solutions Inc. Implantable device for the sustained release of a polypeptide
SI2310042T1 (sl) 2008-07-08 2013-03-29 Novartis Ag Uporaba pasireotida za zdravljenje endogene hiperinzulinemične hipoglikemije
NZ604997A (en) 2008-09-04 2014-07-25 Astrazeneca Pharmaceuticals Lp Sustained release formulations using non-aqueous carriers
SG174355A1 (en) 2009-04-03 2011-10-28 Nestec Sa Improvement in promotion of healthy catch-up growth
ES2705249T3 (es) 2009-06-08 2019-03-22 Amunix Operating Inc Polipéptidos reguladores de glucosa y métodos para su producción y uso
WO2011109787A1 (en) 2010-03-05 2011-09-09 Conjuchem, Llc Methods of administering insulinotropic peptides
US20130137645A1 (en) 2010-07-19 2013-05-30 Mary S. Rosendahl Modified peptides and proteins
US8969293B2 (en) 2010-12-23 2015-03-03 Rani Therapeutics, Llc Therapeutic agent preparations comprising exenatide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
WO2013059323A1 (en) 2011-10-18 2013-04-25 Prolynx Llc Peg conjugates of exenatide
CA2875983A1 (en) 2012-02-08 2013-08-15 Seneb Biosciences, Inc. Treatment of hypoglycemia
WO2015022420A1 (en) 2013-08-16 2015-02-19 Medimmune Limited Gip and glp-1 receptor dual-agonists for the treatment of diabetes
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
ES2887723T3 (es) 2015-05-22 2021-12-27 Univ Leland Stanford Junior Tratamiento de hipoglucemia posbariátrica con exendina(9-39)
WO2017152014A1 (en) 2016-03-04 2017-09-08 Eiger Biopharmaceuticals, Inc. Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
CN110267648A (zh) 2016-11-21 2019-09-20 艾格尔峰生物制药有限公司 毒蜥外泌肽(9-39)的缓冲制剂

Also Published As

Publication number Publication date
CA3024353A1 (en) 2016-12-01
AU2016267052B2 (en) 2022-01-20
US20230346890A1 (en) 2023-11-02
RS62627B1 (sr) 2021-12-31
EP3297653B1 (en) 2021-09-15
US20240000894A1 (en) 2024-01-04
ES2897955T3 (es) 2022-03-03
AU2016267052A1 (en) 2017-12-14
HRP20211285T1 (hr) 2022-01-07
SI3297654T1 (sl) 2021-11-30
PL3297653T3 (pl) 2022-01-31
PT3297654T (pt) 2021-09-06
EP3297654B1 (en) 2021-07-07
AU2016267057B2 (en) 2021-12-23
CY1125147T1 (el) 2023-03-24
EP3297653A1 (en) 2018-03-28
AU2016267057A1 (en) 2017-12-14
US10993992B2 (en) 2021-05-04
DK3297653T3 (da) 2021-10-18
US20180147261A1 (en) 2018-05-31
US20210315974A1 (en) 2021-10-14
ES2887723T3 (es) 2021-12-27
EP3297654A4 (en) 2018-04-11
US11617782B2 (en) 2023-04-04
US10993991B2 (en) 2021-05-04
US20200276272A1 (en) 2020-09-03
US20210290731A1 (en) 2021-09-23
EP3297654A1 (en) 2018-03-28
CA3024358A1 (en) 2016-12-01
EP3297653A4 (en) 2018-12-26
CL2017002911A1 (es) 2018-05-25
EP3936143A1 (en) 2022-01-12
DK3297654T3 (da) 2021-09-06
AU2022201973A1 (en) 2022-04-14
AU2022202506A1 (en) 2022-05-12
US11622995B2 (en) 2023-04-11
PL3297654T3 (pl) 2021-12-20
US20200276271A1 (en) 2020-09-03
US20180117122A1 (en) 2018-05-03
BR112017025000A2 (pt) 2018-08-07
EP3978011A1 (en) 2022-04-06
HUE055728T2 (hu) 2021-12-28
CL2017002913A1 (es) 2018-06-01
BR112017024997A2 (pt) 2018-07-31
WO2016191395A1 (en) 2016-12-01
US10660937B2 (en) 2020-05-26
HUE057301T2 (hu) 2022-05-28
PT3297653T (pt) 2021-10-25
CY1124616T1 (el) 2022-07-22
LT3297653T (lt) 2022-01-10
SI3297653T1 (sl) 2022-01-31
US10639354B2 (en) 2020-05-05
WO2016191394A1 (en) 2016-12-01
HRP20211768T1 (hr) 2022-02-18
RS62368B1 (sr) 2021-10-29

Similar Documents

Publication Publication Date Title
SI3297654T1 (sl) Zdravljenje postbariatrične hipoglikemije z eksendinom(9-39)
SG10202100803WA (en) Endoscope with pannable camera and related method
HK1248552A1 (zh) 使用川地匹坦的治療方法
GB201522243D0 (en) Treatment
GB201502137D0 (en) Treatment
HK1256423A1 (zh) 纖維化治療
HK1249866A1 (zh) 用他塞利昔布進行治療的方法
GB201519450D0 (en) Novel treatment
GB201508841D0 (en) Treatment
HK1232071A1 (zh) 使用 抑制劑治療 感染
RS60316B1 (sr) Lečenje dijabetesa tipa 1 korišćenjem glp-1 i anti-il-21
GB201414366D0 (en) Blood defence
GB201513543D0 (en) Compositions for use in the treatment of diabetes
GB201503008D0 (en) Treatment
AU2015904246A0 (en) Treatment of diabetes
AU2016901862A0 (en) Treatment of diabetes
PT3139948T (pt) Tratamento de diabetes usando glp-1 e anti-il-21
GB201518349D0 (en) Treatment
GB201513922D0 (en) Treatment of hyperpigmentation
GB201515739D0 (en) Treatment
GB201514008D0 (en) Treatment
AU2015902668A0 (en) Fast acting hypoglycaemic treatment ( Hypo-fast)
EP3093013A4 (en) Agent for treating diabetes
GB201407396D0 (en) Confectionary treatment
SG10201400823PA (en) Therapeutic methods and compositions for treating diabetes